{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Kogenate+FS",
    "query": {
      "intervention": "Kogenate FS"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Kogenate+FS&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T02:01:14.367Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00989196",
      "title": "Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Human-cl rhFVIII",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Kogenate FS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2010-05",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2019-10-08",
      "last_synced_at": "2026-09-08T02:01:14.367Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Sacramento, California • Denver, Colorado + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00989196"
    },
    {
      "nct_id": "NCT01184820",
      "title": "Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2010-10-13",
      "completion_date": "2011-10-10",
      "has_results": false,
      "last_update_posted_date": "2018-09-07",
      "last_synced_at": "2026-09-08T02:01:14.367Z",
      "location_count": 4,
      "location_summary": "Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01184820"
    },
    {
      "nct_id": "NCT00623480",
      "title": "Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recombinant Factor VIII (Kogenate FS, BAY14-2222)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "12 Years to 50 Years · Male only"
      },
      "enrollment_count": 84,
      "start_date": "2008-03",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2014-11-17",
      "last_synced_at": "2026-09-08T02:01:14.367Z",
      "location_count": 28,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Orange, California + 23 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623480"
    },
    {
      "nct_id": "NCT00621673",
      "title": "Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Kogenate (BAY 14-2222)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "12 Years to 60 Years · Male only"
      },
      "enrollment_count": 1,
      "start_date": "2006-05",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2014-12-18",
      "last_synced_at": "2026-09-08T02:01:14.367Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • Las Vegas, Nevada",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00621673"
    },
    {
      "nct_id": "NCT02396862",
      "title": "Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "16 Years and older · Male only"
      },
      "enrollment_count": 272,
      "start_date": "2015-12-09",
      "completion_date": "2018-03-26",
      "has_results": false,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-09-08T02:01:14.367Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02396862"
    },
    {
      "nct_id": "NCT00629837",
      "title": "Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Factor VIII (Kogenate FS, BAY14-2222)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "12 Years to 60 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2005-09",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2014-11-18",
      "last_synced_at": "2026-09-08T02:01:14.367Z",
      "location_count": 2,
      "location_summary": "Davis, California • Orange, California",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00629837"
    },
    {
      "nct_id": "NCT02586012",
      "title": "Weight-based Dosing in Hemophilia A",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "rFVIII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Craig Seaman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2015-09",
      "completion_date": "2020-01-10",
      "has_results": true,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-09-08T02:01:14.367Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02586012"
    },
    {
      "nct_id": "NCT00782470",
      "title": "Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hematologic Disease",
        "Blood Coagulation Disorders"
      ],
      "interventions": [
        {
          "name": "Recombinant Factor VIII (Kogenate, BAY 14-2222)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "29 Years",
        "sex": "MALE",
        "summary": "14 Years to 29 Years · Male only"
      },
      "enrollment_count": 38,
      "start_date": "2007-12",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2014-11-03",
      "last_synced_at": "2026-09-08T02:01:14.367Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Denver, Colorado • Peoria, Illinois + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Jefferson City",
          "state": "Missouri"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782470"
    },
    {
      "nct_id": "NCT03405337",
      "title": "Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "FVIII products",
          "type": "DRUG"
        },
        {
          "name": "Conventional FVIII replacement therapies",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2018-02-14",
      "completion_date": "2018-06-13",
      "has_results": false,
      "last_update_posted_date": "2018-09-27",
      "last_synced_at": "2026-09-08T02:01:14.367Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03405337"
    },
    {
      "nct_id": "NCT00623727",
      "title": "BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rFVIII-FS/pegylated liposomes (BAY79-4980)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rFVIII-FS/WFI (BAY14-2222)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "12 Years to 70 Years · Male only"
      },
      "enrollment_count": 143,
      "start_date": "2008-06",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2013-07-15",
      "last_synced_at": "2026-09-08T02:01:14.367Z",
      "location_count": 20,
      "location_summary": "Orange, California • Sacramento, California • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623727"
    }
  ]
}